220022-94-6

Basic information

• Product Name: Alanine, N,N,2-trimethyl- (9CI)
• Synonyms: Alanine, N,N,2-trimethyl- (9CI);DL-Alanine, N,N,2-triMethyl-;2-alanine betaine;2-(dimethylazaniumyl)-2-methylpropanoate
• CAS NO: 220022-94-6
• Molecular Formula: C₆H₁₃NO₂
• Molecular Weight: 131.17292
• Product Categories: AMINETERTIARY
• Mol File: 220022-94-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Alanine, N,N,2-trimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Alanine, N,N,2-trimethyl- (9CI)(220022-94-6)
• EPA Substance Registry System: Alanine, N,N,2-trimethyl- (9CI)(220022-94-6)

Safety Data

• Hazardous Substances Data: 220022-94-6(Hazardous Substances Data)

Usage

General Description

Alanine, N,N,2-trimethyl- (9CI) is a chemical compound with the molecular formula C6H14N2O2. It is a derivative of the amino acid alanine, with an additional trimethyl group attached to the nitrogen atom. Alanine, N,N,2-trimethyl- (9CI) has been studied for its potential biological and pharmacological properties, including its role as a neuroprotective agent. It may also have applications in the development of new therapeutic drugs and as a precursor for the synthesis of other organic compounds. However, further research is needed to fully understand the potential uses and effects of Alanine, N,N,2-trimethyl- in various fields.

Upstream product

• 50-00-0 formaldehyd 
• 62-57-7 2-Aminoisobutyric acid 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 124-40-3 dimethyl amine 
• 151-50-8 potassium cyanide 
• 67-64-1 acetone 
• 64-18-6 formic acid 
• 7732-18-5 water 
• 286011-63-0 N,N(diMe)-Aib-OBzl 
• 146000-39-7 N-tert-butoxycarbonyl-N-methyl-α-aminoisobutyric acid 
• 514844-41-8 Boc-N(Me)-Aib-OBzl 

Downstream Products

• 140653-59-4 α-dimethylamino-isobutyric acid methyl ester 
• 124-38-9 carbon dioxide 
• 124-40-3 dimethyl amine 
• 67-64-1 acetone 
• 959840-21-2 C₂₄H₃₂FN₅O₃ 

Relevant articles and documents

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

New active series of growth hormone secretagogues

New growth hormone secretagogue (GHS) analogues were synthesized and evaluated for growth hormone releasing activity. This series derived from EP-51389 is based on a gem-diamino structure. Compounds that exhibited higher in vivo GH-releasing potency than hexarelin in rat (subcutaneous administration) were then tested per os in beagle dogs and for their binding affinity to human pituitary GHS receptors and to hGHS-R 1a. Compound 7 (JMV 1843, H-Aib-(D)-Trp-(D)-gTrp-formyl) showed high potency in these tests and was selected for clinical studies.